Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2125444 | 0.96 | CYP3A4 (0.52) | CYP2C9CYP2C19CYP19A1CYP2D6CYP3A4 | |
| SCHEMBL28176277 | 0.84 | CDK2 (0.47) | CYP2C9CYP2C19CYP19A1CYP2D6CYP3A4 | |
| SCHEMBL2124284 | 0.83 | CYP11B1 (0.61) | CYP19A1SMN1; SMN2CYP11B1CYP11B2IDO1 | |
| SCHEMBL2122561 | 0.81 | CYP11B1 (0.43) | CYP2C9CYP2C19CYP19A1CYP2D6CYP3A4 | |
| SCHEMBL2123894 | 0.79 | CYP3A4 (0.48) | CYP2C9CYP2C19CYP19A1CYP2D6CYP3A4 | |
| SCHEMBL2123501 | 0.78 | PPARA (0.50) | CYP2C9CYP2C19CYP19A1CYP2D6CYP3A4 | |
| SCHEMBL27463979 | 0.76 | CDK1 (0.41) | SMN1; SMN2MAPTCCNE2CCNE1CDK2 | |
| SCHEMBL2124589 | 0.76 | CYP3A4 (0.45) | CYP2C9CYP2C19CYP19A1CYP2D6CYP3A4 | |
| SCHEMBL2123555 | 0.75 | CYP3A4 (0.44) | CYP2C9CYP2C19CYP19A1CYP2D6CYP3A4 | |
| SCHEMBL2122223 | 0.74 | CYP2D6 (0.43) | CYP2C9CYP2C19CYP19A1CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735388-B2 | Heterocyclic compounds with affinity to muscarinic receptors | ABBVIE B.V. (NL) | 2014-05-27 | — | — | US | disclosed |
| US-20140080861-A1 | HETEROCYCLIC COMPOUNDS IWTH AFFINITY TO MUSCARINIC RECEPTORS | ABBVIE B.V.A (NL) | 2014-03-20 | — | — | US | disclosed |
| US-8586606-B2 | Heterocyclic compounds with affinity to muscarinic receptors | ABBVIE B.V. (NL) | 2013-11-19 | — | — | US | disclosed |
| US-20120095039-A1 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | SOLVAY PHARMACEUTICALS B.V. | 2012-04-19 | — | — | US | disclosed |
| US-8084473-B2 | Heterocyclic compounds with affinity to muscarinic receptors | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-12-27 | — | — | US | disclosed |
| CN-101939311-A | Heterocyclic compounds with affinity for muscarinic receptors | SOLVAY PHARM BV | 2011-01-05 | — | — | CN | disclosed |
| EP-2150543-A2 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | Solvay Pharmaceuticals B.V. (NL) | 2010-02-10 | — | — | EP | disclosed |
| US-20090018160-A1 | Heterocyclic Compounds with Affinity to Muscarinic Receptors | ABBVIE B.V. (NL) | 2009-01-15 | — | — | US | disclosed |
| WO-2008129054-A2 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095039-A1 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | CHRM3, CHRM5, CHRM2 | CYP2C9 700/4885CYP2C19 482/4885CYP19A1 820/4885 |
| US-20140080861-A1 | HETEROCYCLIC COMPOUNDS IWTH AFFINITY TO MUSCARINIC RECEPTORS | CHRM3, CHRM4, CHRM5 | CYP2C9 661/4885CYP2C19 482/4885CYP19A1 287/4885 |
| US-20090018160-A1 | Heterocyclic Compounds with Affinity to Muscarinic Receptors | CHRM3, CHRM2, CHRM1 | CYP2C9 836/4885CYP2C19 1027/4885CYP19A1 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.